Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | +1.66% | -3.15% | +28.11% |
Financials (USD)
Sales 2024 * | 3.63M | Sales 2025 * | 6.18M | Capitalization | 1.32B |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -191M | EV / Sales 2024 * | 226 x |
Net cash position 2024 * | 502M | Net cash position 2025 * | 403M | EV / Sales 2025 * | 149 x |
P/E ratio 2024 * |
-8.43
x | P/E ratio 2025 * |
-8.66
x | Employees | 171 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.5% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | -0.51% | ||
1 week | -4.45% | ||
Current month | +6.85% | ||
1 month | -2.96% | ||
3 months | -4.05% | ||
6 months | +142.83% | ||
Current year | +26.21% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 14 M€ | -3.61% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 25.96 | +1.51% | 126 063 |
24-05-13 | 25.57 | -0.51% | 593,875 |
24-05-10 | 25.7 | +0.23% | 397,446 |
24-05-09 | 25.64 | -2.62% | 323,004 |
24-05-08 | 26.33 | -1.75% | 340,145 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.21% | 1.32B | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+42.10% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- FDMT Stock